Technical platform-NAPPA
From efficient antibody screen to instant self-assembly of antibody fragments, we have the world’s most powerful pipeline for developing multi-specific antibodies (MsAbs).
NAPPA™
MsAb has the obvious advantage of being able to target multiple switches during T-cell based therapy, but its true potential has been limited by the challenging protein engineering and production involved in its making. Our revolutionary NAPPA technology allows pre-storage of individual antibody fragments (nanobody, scFv, and Fab) targeting different antigens, and their self-assembly “on the fly” to form MsAbs of any order of specificity during a personalized cancer treatment. Such technology allows the construction of a library of antibody fragments (or warheads) to be used with the NAPPA technology for strategic delivery of MsAbs during a treatment.
NATIVE ANTIGEN™
Antibody-antigen recognition is conformation specific. For many antigens exposed on the cell surface, however, their native conformations strongly depend on the membrane environment. Our Native Antigen technology uses functionalized membrane scaffold protein to specifically recruit membrane proteins from the cell surface for lipid nanodisc assembly. The efficient incorporation of membrane antigens into lipid nanodiscs allows for throughput production of natively displayed antigens for either immunization or phage/yeast display. This technology can be used for a variety of membrane antigens such as Type I/II membrane proteins, GPCRs, ion channels, and transporters. The Native Anigen technology allows us to construct a high quality library of antibody fragments for making MsAbs.
- 2-3F, Bldg.1, No.88 Da'erwen Rd., China(Shanghai) Pilot Free Trade Zone
- +021-5838-6095
- assembly@assemblymedicine.com